This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Estimates for Arthur J. Gallagher & Co. (AJG - Free Report) have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The stock has seen the Zacks Consensus Estimate for 2018 and 2019 earnings being raised 0.3% each to $3.46 and $3.85, respectively. The company provides insurance brokerage, consulting and third party claims settlement plus administration services.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ BRO AON WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN KTN WFC.PRY WFC.PRX WFC.PRW Y WFC.PRV
Form S-8 POS As filed with the Securities and Exchange Commission on June 29, 2018 Registration Statement No. 333-178906
15-15D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
AIG.WS AVF KTN AIG 8685 AON
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected](# @;V)J#3P\+TQI;F5A8F)D [email protected]":#"08*T%$,[email protected]@T2*P41DB!N-8BU!L3*![%[email protected]@@@JD02#P#ZF5D MN ]D,3 P$D/\9^S\ [email protected] ((;"P\-"F5N9'-T
CORRESP Aon plc
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8Q(# @;V)J#3P\+TQI;F5A
CORRESP Aon plc 122 Leadenhall Street London
Wallace Weitz's 13F portfolio value decreased marginally from $2.40B to $2.37B. The number of positions decreased from 77 to 75.
ALSN DLTR WEHIX LBTYK EQC.PRD RWT FOX RRS BATRA MLM LSXMB LH FB TMO CCV LSXMA QVCB WFC.PRL CCZ WFC.PRJ GLIBA QVCA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP AGN WFC.PRO WFC.PRN EQCO AAPL MON WFC.PRY WFC.PRX TUP WFC.PRW DEO WFC.PRV LBRDB MRVL TDG MUSA LBTYB MA AXTA LBTYA LBRDK AON RGRYY JPM CCV.CL LSXMK LBRDA TXN DISCA KMX LBTY PXD CAXPF HPE AMZN LILAB CMP DXC CMCSK EQC LGF LEXEA GWRE TWC RGRLF RRC BRK.A GOOGL LILAK KTN XOXO FLIR AHBIF FOXA WFCNP BATRK BATRR RRL GOOG CHTR LVNTB VMC ACN LVNTA BATRB DXC.WI XOMA ORCL MKL WFC WFC.WS WAIR BUD ACIW FWONB CFX CMCSA QRTEA FWONA INS V BKNG PX OCLCF FWONK LGF.A LGF.B DHR LILA
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Law firm Latham & Watkins closed a deal to take 407,000 square feet at the former Time & Life Building, now called 1271 Avenue of the Americas.
MGM HCN FOX WU UL UN UNLYF ULVR WELL.PRI HCN.PRJ CHKP UNLNF AON HCN.PRI MDT EMN.WS HRL CBG EMN KTN WELL ACN FOXA CBRE
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
Silicon Investor Message Boards
This table lists all message boards related to KTN / Structured Products CorTS, Aon Capital A, 8.205% Certificates on message board site Silicon Investor.
|KTNV ** Profitable and Undervalued||KTNX Kentex Energy Inc has fiancing in place..could move|
as of ET